postpartum%20hemorrhage
POSTPARTUM HEMORRHAGE
Postpartum hemorrhage is defined as blood loss of ≥500 mL for vaginal delivery or 1000 mL for abdominal (Caesarean) delivery after completion of the 3rd stage of labor.
Another proposed definition is a 10% fall in hematocrit value.
Since the clinical estimation of the amount of blood loss is typically inaccurate, the diagnosis of postpartum hemorrhage remains a subjective clinical assessment of the amount of blood loss that jeopardizes a woman's hemodynamic stability.
Postpartum hemorrhage may produce hemodynamic instability during the 1st 24 hours after delivery.

Monitoring

Monitor Response to Treatment

  • Sensorium
  • Vital signs
  • Urine output
    • A urine output of >30 mL/hr is an objective sign of adequate renal perfusion
  • Complete blood count (CBC), coagulation
    • Blood sample is drawn to assess hematologic and metabolic profile, electrolytes, coagulation, acid-base oxygenation status
  • Evaluate tissue perfusion
    • Measure serum lactate and base deficit 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Vincent YT Cheung, 01 Dec 2015

Ultrasonography has been widely used as a routine component of antenatal care. During the assessment of the foetus and the placenta, an adnexal mass may be discovered at the time of the ultrasound examination. Occasionally, an adnexal mass can also be suspected either on physical examination or as a result of clinical symptoms.
26 Feb 2017
Placement of cervical pessary in women with short cervices and singleton pregnancies does not lower the risk of having preterm births, according to the results of a meta-analysis.
Asykin Ismail, Dr. Jazlan Joosoph, 17 Mar 2018
Obstetrician and gynaecologist at Raffles Hospital, Dr Jazlan Joosoph, shares the lowdown on the condition, diagnosis and treatment options.
Roshini Claire Anthony, 07 Sep 2016

Estrogen receptor α (ESR1) mutations Y537S and D538G are associated with reduced overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, according to findings of a secondary analysis of the BOLERO-2* clinical trial.